These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16103113)

  • 1. Proteasomes mediate prolactin-induced receptor down-regulation and fragment generation in breast cancer cells.
    Lu JC; Piazza TM; Schuler LA
    J Biol Chem; 2005 Oct; 280(40):33909-16. PubMed ID: 16103113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactin involvement in breast cancer.
    Vonderhaar BK
    Endocr Relat Cancer; 1999 Sep; 6(3):389-404. PubMed ID: 10516853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trafficking, ubiquitination, and down-regulation of the human platelet-activating factor receptor.
    Dupré DJ; Chen Z; Le Gouill C; Thériault C; Parent JL; Rola-Pleszczynski M; Stankova J
    J Biol Chem; 2003 Nov; 278(48):48228-35. PubMed ID: 14500726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stabilization of prolactin receptor in breast cancer cells.
    Li Y; Clevenger CV; Minkovsky N; Kumar KG; Raghunath PN; Tomaszewski JE; Spiegelman VS; Fuchs SY
    Oncogene; 2006 Mar; 25(13):1896-902. PubMed ID: 16278670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights in prolactin: pathological implications.
    Bernard V; Young J; Chanson P; Binart N
    Nat Rev Endocrinol; 2015 May; 11(5):265-75. PubMed ID: 25781857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammary gland development and the prolactin receptor.
    Binart N; Ormandy CJ; Kelly PA
    Adv Exp Med Biol; 2000; 480():85-92. PubMed ID: 10959413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.
    Langenheim JF; Chen WY
    Breast Cancer Res Treat; 2005 Apr; 90(3):281-93. PubMed ID: 15830142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should prolactin be reconsidered as a therapeutic target in human breast cancer?
    Goffin V; Touraine P; Pichard C; Bernichtein S; Kelly PA
    Mol Cell Endocrinol; 1999 May; 151(1-2):79-87. PubMed ID: 10411322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin as an autocrine/paracrine growth factor in human cancer.
    Ben-Jonathan N; Liby K; McFarland M; Zinger M
    Trends Endocrinol Metab; 2002 Aug; 13(6):245-50. PubMed ID: 12128285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin mediated intracellular signaling in mammary epithelial cells.
    Hynes NE; Cella N; Wartmann M
    J Mammary Gland Biol Neoplasia; 1997 Jan; 2(1):19-27. PubMed ID: 10887516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.
    Gutzman JH; Miller KK; Schuler LA
    J Steroid Biochem Mol Biol; 2004 Jan; 88(1):69-77. PubMed ID: 15026085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications.
    Gadd SL; Clevenger CV
    Mol Endocrinol; 2006 Nov; 20(11):2734-46. PubMed ID: 16840534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of transglutaminase or phospholipase A2 inhibitors on down-regulation of prolactin receptors and stimulation of casein and DNA synthesis in mammary gland explants.
    Dusanter-Fourt I; Djiane J; Houdebine LM
    Mol Cell Endocrinol; 1983 Aug; 31(2-3):287-99. PubMed ID: 6138286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both proteasomes and lysosomes degrade the activated erythropoietin receptor.
    Walrafen P; Verdier F; Kadri Z; Chrétien S; Lacombe C; Mayeux P
    Blood; 2005 Jan; 105(2):600-8. PubMed ID: 15358619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactin regulation of cryptic prolactin receptors in cultured rat mammary tumor cells.
    Costlow ME; Hample A
    J Cell Physiol; 1984 Mar; 118(3):247-52. PubMed ID: 6321522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress in prolactin receptor research].
    Tan DY; Peng XP
    Sheng Li Ke Xue Jin Zhan; 2012 Feb; 43(1):17-23. PubMed ID: 22582593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of prolactin binding by cyclosporine A on MCF7 breast tumour cell line.
    Bernard DJ; Maurizis JC; Sauvezie B; Bignon YJ; Chassagne J; Chollet P; Plagne R
    Anticancer Res; 1991; 11(6):2147-51. PubMed ID: 1776854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin: the forgotten hormone of human breast cancer.
    Vonderhaar BK
    Pharmacol Ther; 1998 Aug; 79(2):169-78. PubMed ID: 9749881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a novel and functional human prolactin receptor isoform (deltaS1PRLr) containing only one extracellular fibronectin-like domain.
    Kline JB; Rycyzyn MA; Clevenger CV
    Mol Endocrinol; 2002 Oct; 16(10):2310-22. PubMed ID: 12351696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models.
    Leehy KA; Truong TH; Mauro LJ; Lange CA
    J Steroid Biochem Mol Biol; 2018 Feb; 176():88-93. PubMed ID: 28442393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.